Update
$Matinas BioPharma(MTNB.US$ New In Vitro Data Showing Matinas BioPharma's LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024
3 MINUTES AGO, 7:00 AM EDT
VIA GLOBENEWSWIRE
BEDMINSTER, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces new in vitro data showing the use of LNCs for the delivery of small oligonucleotides was presented yesterday in a poster session at TIDES USA 2024: Oligonucleotide & Peptide Therapeutics, a hybrid in-person and virtual conference underway in Boston.
The poster, "Intracellular Delivery of Small Oligonucleotides with Lipid Nanocrystals (LNCs): in vitro studies," was presented by Hui Liu, PhD, Chief Technology Officer of Matinas, and is available here. The poster discusses in vitro studies demonstrating the avid uptake of LNC formulations of various cytokine-targeted small oligonucleotides in murine macrophages, with up to 70% gene knockdown observed for each targeted cytokine.
"There has been heightened interest in small oligonucleotides in multiple therapeutic areas, yet a major barrier to their use is systemic delivery, which can lead to toxicity and adverse immunogenicity," said Dr. Liu. "These in vitro studies showed that our LNCs can successfully encapsulate and protect ASOs, siRNA and other small oligonucleotides even when exposed to gastric fluid and can deliver them to a variety of cells with demonstrable biological activity. These characteristics make LNCs a highly promising oral drug delivery platform for future applications requiring oral delivery of small oligonucleotides."
3 MINUTES AGO, 7:00 AM EDT
VIA GLOBENEWSWIRE
BEDMINSTER, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces new in vitro data showing the use of LNCs for the delivery of small oligonucleotides was presented yesterday in a poster session at TIDES USA 2024: Oligonucleotide & Peptide Therapeutics, a hybrid in-person and virtual conference underway in Boston.
The poster, "Intracellular Delivery of Small Oligonucleotides with Lipid Nanocrystals (LNCs): in vitro studies," was presented by Hui Liu, PhD, Chief Technology Officer of Matinas, and is available here. The poster discusses in vitro studies demonstrating the avid uptake of LNC formulations of various cytokine-targeted small oligonucleotides in murine macrophages, with up to 70% gene knockdown observed for each targeted cytokine.
"There has been heightened interest in small oligonucleotides in multiple therapeutic areas, yet a major barrier to their use is systemic delivery, which can lead to toxicity and adverse immunogenicity," said Dr. Liu. "These in vitro studies showed that our LNCs can successfully encapsulate and protect ASOs, siRNA and other small oligonucleotides even when exposed to gastric fluid and can deliver them to a variety of cells with demonstrable biological activity. These characteristics make LNCs a highly promising oral drug delivery platform for future applications requiring oral delivery of small oligonucleotides."
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
